Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Mar 26.

Published in final edited form as: Mol Pharm. 2017 Nov 29;15(1):83–96. doi: 10.1021/acs.molpharmaceut.7b00734

Table 3.

Pharmacokinetic parameters (% CV) of total phospholipids after 50 mg/kg doses of sHDL, sHDL-PEG2k (5%), sHDL-PEG2k (10%) and sHDL-PEG5k (5%) treatments.

Parameters	Groups
Parameters	sHDL	sHDL-PEG2k (5%)	sHDL-PEG2k (10%)	sHDL-PEG5k (5%)
C_max^a (mg/dL)	383.9 (28.0)	438.1 (9.5)^ns	477.0 (27.3)^ns	578.0 (4.8)^*
T_max^b (h)	0.38 (38.5)	0.88 (28.6)^*	1.6 (46.2)^*	1.0 (0)^***
AUC^c *(mgh/dL)**	2071 (21.7)	3042 (26.2)^ns	4473 (11.8)^***	6108 (18.5)^***
K₁₀^d (h-1)	0.17 (34.5)	0.11 (54.9)^ns	0.072 (19.7)^*	0.065 (37.9)^*
T_1/2^e (h)	4.59 (43.3)	8.62 (46.9)^ns	9.96 (18.2)^**	12.5 (38.2)^*
CL^f (dL/h)	0.014 (23.6)	0.0088 (20.5)^*	0.0057 (10.7)^**	0.0044 (30.4)^**
V_SS^g (dL)	0.083 (19.7)	0.10 (37.2)^ns	0.084 (28.0)^ns	0.074 (27.4)^ns

^a

C_max: the maximum plasma concentration of phospholipids

^b

T_max: the time to observe C_max

^c

AUC: the area under the curve in plot of concentration of phospholipids against time

^d

K₁₀: elimination rate constant

^e

T_1/2: the half-life of elimination

^f

CL: total clearance for phospholipids

^g

V_SS: volume of distribution for phospholipids. Data was shown as mean with CV%.

^*

p<0.05

^**

p<0.01

^***

p<0.001

^****

p<0.0001

^ns

: no significant difference compared with sHDL group.